Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8048917 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Nov, 2022
(4 months ago) | |
US6818787 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(2 years from now) | |
US8026279 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Nov, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8686034 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Jan, 2025
(1 year, 9 months from now) | |
US8114909 | AZURITY | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
Apr, 2026
(3 years from now) | |
US8795725 | AZURITY | GABA analog prodrug sustained release oral dosage forms |
Jun, 2029
(6 years from now) |
Market Authorisation Date: 06 April, 2011
Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; Management of postherpetic neuralgia (phn) in adults
Dosage: TABLET, EXTENDED RELEASE;ORAL
54
United States
11
Japan
10
China
10
European Union
9
Australia
8
Korea, Republic of
7
Norway
6
Israel
6
New Zealand
5
South Africa
5
Mexico
5
Hong Kong
5
Canada
4
Russia
4
Spain
3
Denmark
3
Austria
3
Brazil
2
Hungary
2
Singapore
2
Portugal
2
Cyprus
1
Slovenia
1
Germany
1
Poland
1
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic